Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
30 Mar 2024
// PHARMABIZ
27 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/03/27/2853117/0/en/Oncopeptides-and-Vector-Pharma-FZCO-Announce-Collaboration-to-Provide-Pepaxti-to-Patients-in-the-Middle-East-and-North-Africa.html
08 Jan 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/01/08/2805433/0/en/Vector-Pharma-FZCO-Announce-Exclusive-Distribution-Agreement-with-Ascendis-Pharma-A-S-for-Skytrofa-lonapegsomatropin-and-Yorvipath-palopegteriparatide-in-Gulf-Cooperation-Council-C.html
14 Nov 2022
// PRNEWSWIRE
https://www.biospace.com/article/world-orphan-drug-alliance-partnering-with-decisive-consulting-to-broaden-access-capability/
13 May 2022
// BIOSPECTRUMASIA
https://www.biospectrumasia.com/news/25/20290/woda-combining-forces-to-reach-patients-with-rare-diseases-across-globe.html
28 Apr 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/eversana-and-vector-pharma-fzco-announce-strategic-partnership-to-expand-commercialisation-services-throughout-middle-east-and-north-africa-301534936.html
Details:
Under the collaboration, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, to patients in the MENA region for patients with multiple myeloma.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Brand Name: Pepaxti
Study Phase: ApprovedProduct Type: Peptide
Recipient: Oncopeptides
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2024
Lead Product(s) : Melphalan Flufenamide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Oncopeptides
Deal Size : Undisclosed
Deal Type : Collaboration
Oncopeptides Partners with Vector to Distribute Pepaxti in MENA for Multiple Myeloma
Details : Under the collaboration, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, to patients in the MENA region for patients with multiple myeloma.
Brand Name : Pepaxti
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 30, 2024
Details:
Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Brand Name: Pepaxti
Study Phase: ApprovedProduct Type: Peptide
Recipient: Oncopeptides
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 27, 2024
Lead Product(s) : Melphalan Flufenamide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Oncopeptides
Deal Size : Undisclosed
Deal Type : Collaboration
Oncopeptides and Vector Pharma Announce Collaboration to Provide Pepaxti in MENA Region
Details : Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.
Brand Name : Pepaxti
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 27, 2024
Details:
Vector will distribute Skytrofa (lonapegsomatropin-tcgd) for pediatric growth hormone deficiency and Yorvipath for adult hypoparathyroidism in the GCC countries, using its sales expertise.
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Brand Name: Skytrofa
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Ascendis Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 08, 2024
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Ascendis Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Vector Pharma Signs Distribution Agreement for Skytrofa and Yorvipath
Details : Vector will distribute Skytrofa (lonapegsomatropin-tcgd) for pediatric growth hormone deficiency and Yorvipath for adult hypoparathyroidism in the GCC countries, using its sales expertise.
Brand Name : Skytrofa
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 08, 2024
Details:
Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.
Lead Product(s): Ixabepilone,Capecitabine
Therapeutic Area: Oncology Brand Name: Ixempra
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: R-Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 22, 2021
Lead Product(s) : Ixabepilone,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : R-Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East
Details : Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.
Brand Name : Ixempra
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 22, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?